ArticleClinical rheumatology2026
Exploring the relationship between XDH gene variants and serum urate and xanthine dehydrogenase levels in gout.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGout is a type of arthritis caused by high levels of urate in the body, leading to inflammation and joint pain. Xanthine dehydrogenase (XDH) is a key enzyme in urate biosynthesis, and genetic variations in its XDH gene can influence the amount or activity of the enzyme, as well as the levels of urate produced.
objectivesThis study aimed to explore the association of two single nucleotide variants (SNVs) in the XDH gene with gout susceptibility in the Mexican population, as well as their correlation with urate and XDH levels.
methodsGenotyping of rs17323225 and rs17011368 XDH SNVs was performed in 41 gout patients and 40 controls using real-time PCR. Urate levels were measured by a colorimetric method, and XDH levels by ELISA. Genotypic distributions were analyzed, and associations were estimated using logistic regression models.
resultsUrate and XDH levels were significantly higher in patients than in controls (p = 0.0004 and p = 0.010, respectively). For the rs17323225 variant, the TT genotype was associated with an increased risk of gout compared to controls (OR = 3.69, 95% CI = 1.06-12.8, p = 0.04). Furthermore, individuals with the TT genotype had higher urate and XDH levels than those with other genotypes (p < 0.001 and p = 0.043, respectively).
conclusionThe rs17323225 variant of the XDH gene may be a genetic risk factor for gout in the Mexican population. These findings suggest that XDH genetic variability contributes to urate metabolism dysregulation and could aid in identifying individuals at higher genetic risk for gout, supporting personalized prevention and treatment approaches. Key Points • Xanthine dehydrogenase (XDH) is an enzyme that catalyzes the sequential conversion of hypoxanthine to xanthine, and of xanthine to urate. • The XDH rs17323225 TT genotype is significantly associated with higher levels of serum urate and XDH, suggesting a functional role in urate biosynthesis. • XDH genotyping may help identify individuals at higher risk of gout and guide tailored urate-lowering or xanthine dehydrogenase-targeted therapies.
Indexed as
Identifiers
41729472What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.